@article{article, title  = {{A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2013}},

 month = {{5}},

 author = {{Wolin EM and Jarzab B and Eriksson B and Walter T and Toumpanakis C and Morse M and Tomassetti P and Weber M and Fogelman DR and Ramage J and Poon D et al}},

 doi = {{10.1200/jco.2013.31.15_suppl.4031}},

 volume = {{31}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{15_suppl}},

 pages = {{4031-4031}},

 note = {{Accessed on 2024/12/21}}}